Please ensure Javascript is enabled for purposes of website accessibility

AFLAC Rides the Stronger Yen to Earnings Growth

By Dan Caplinger - Apr 26, 2016 at 5:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The insurance provider got a big boost from a reversal in the dollar's strength.

Image source: Aflac.

Supplemental health insurance specialist AFLAC (AFL -1.28%) differs from major U.S. health insurers like UnitedHealth Group (UNH -2.35%) in two key ways. First, Aflac offers supplemental products that differ from the basic health coverage UnitedHealth provides. But more importantly in the recent past, Aflac gets the bulk of its revenue from the Japanese insurance market, and the strength of the U.S. dollar in recent years has crimped Aflac's overall growth prospects. Coming into Tuesday's first-quarter financial report, Aflac investors had high hopes the insurer might finally start to see that dynamic reverse itself, and Aflac's results confirmed the recent strength of the Japanese yen and its positive impact on the insurance giant's earnings.

Let's look more closely at the latest from Aflac and what investors should expect in the future.

Aflac builds some positive momentum
Aflac's first-quarter results exceeded expectations in all respects. Total revenue climbed to $5.45 billion, up 4.3% and greatly exceeding the $5.26 billion most investors were expecting to see from the specialty insurer. Net income climbed more than 10% to $731 million, and that produced diluted earnings of $1.74 per share, beating the consensus forecast by more than a dime.

A closer look at the numbers shows just how much Aflac's business is affected by foreign exchange rates. The exchange rate between the Japanese yen and the U.S. dollar moved in the yen's favor compared to the year-ago period for the first time in several quarters, with the rate moving from 119.16 yen per dollar last year to 115.35 yen per dollar this year. Aflac estimated that the stronger yen added about $0.03 per share to operating earnings for the quarter, and that's a nice change of pace from the hits Aflac has taken in the past.

With the dollar's impact taken away, Aflac's growth prospects were easier to see in the company's financials. The Aflac Japan unit saw premium income rise 0.1% in local-currency terms, but that amounted to a 3.3% increase in dollar terms because of the yen's strength. Similarly, a 1.7% drop in local-currency-measured net investment income turned into a 1.4% rise in dollar terms, and that helped produce a 2.4% rise in operating earnings on a 3% rise in sales for the unit. Total new annualized premium sales climbed almost 16%, with first-sector sales of child-endowment and similar products accounting for nearly all of the growth even as cancer insurance and medical products sales inched upward by just 1%.

The U.S. segment also posted solid numbers. Premium income rose 2.1%, and net investment income jumped 5.1%. Pretax profit margins jumped more than two and a half percentage points, and total new annualized premium sales rose as well.

Aflac CEO Daniel Amos celebrated his company's results. "We continue to believe that the changes we made to our career and broker management infrastructure have created a foundation for greater long-term growth opportunities," Amos said. Yet the CEO also reminded investors that solid results in Japan are likely to deteriorate later in the year in both the first-sector and third-sector markets.

Can Aflac stay ducky?
Aflac's expectations for long-term growth remain intact. In Japan, Aflac believes 4% to 6% growth in third-sector products in Japan is sustainable, and the company still thinks a 3% to 5% rise in new annualized premiums for the full year is attainable. Earnings guidance for $6.17 to $6.41 per share for 2016 is still Aflac's annual objective, but a lower dollar could produce second-quarter earnings of $1.55 to $1.82 per share, which would be toward the high end of investor expectations. Aflac also expects to spend $1.4 billion on stock buybacks this year, using the repatriation of 120 billion to 150 billion yen to finance repurchases.

The need for more specialized insurance coverage among workers could continue to propel Aflac higher. In the U.S., Aflac has great success in selling its products through the workplace, and the company has the flexibility to do things UnitedHealth and its peers simply can't. The impact of healthcare reform has been to standardize the regular coverage UnitedHealth offers, but Aflac can still tailor coverage to certain diseases or medical conditions. That has value for buyers, and Aflac should continue to succeed if it can market its products well.

Aflac investors weren't immediately pleased with the results, sending the stock down 2% in the first hour of after-market trading following the announcement. In order to hold onto its recent share-price gains, Aflac will need to demonstrate that the anticipated pressure to its Japanese business won't result in dramatically slower long-term growth.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aflac Incorporated Stock Quote
Aflac Incorporated
$55.52 (-1.28%) $0.72
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
$505.24 (-2.35%) $-12.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.